Microfluidic apoptosis chip for drug screening to improve and personalize cancer therapy

F. Wolbers, H.R. Franke, Helene Andersson, I. Vermes, Albert van den Berg

    Research output: Chapter in Book/Report/Conference proceedingConference contributionAcademic

    Abstract

    Currently, the knowledge on breast cancer treatment is increasing, however, there are still hardly any assays present to match patients to the right form of therapy to enhance the therapeutic effectiveness. Therefore a microfluidic device is developed to analyse the hormonal and chemosensitivity of first breast cancer cell lines and in a later stage a patient’s own tumour cells. As the main goal of breast cancer therapy is to kill tumour cells, the degree of apoptosis is assessed.
    Original languageUndefined
    Title of host publicationHighlights in Biomedical Technology 2008
    Place of PublicationEnschede
    PublisherUniversity of Twente
    Pages101-104
    Number of pages4
    ISBN (Print)978-90-365-2762-0
    Publication statusPublished - 20 Nov 2008
    EventSymposium Highlights in Biomedical Technology 2008 - University of Twente, Enschede, Netherlands
    Duration: 20 Nov 200820 Nov 2008

    Publication series

    Name
    PublisherUniversity of Twente

    Other

    OtherSymposium Highlights in Biomedical Technology 2008
    CountryNetherlands
    CityEnschede
    Period20/11/0820/11/08

    Keywords

    • EWI-14970
    • METIS-256142
    • IR-62712

    Cite this

    Wolbers, F., Franke, H. R., Andersson, H., Vermes, I., & van den Berg, A. (2008). Microfluidic apoptosis chip for drug screening to improve and personalize cancer therapy. In Highlights in Biomedical Technology 2008 (pp. 101-104). Enschede: University of Twente.